Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments October 13, 2026 11:00 AM EDT
Company Participants
Arnon Rosenthal – Co-Founder, CEO & Director
Eric Brown – Director of Antibody Discovery & Protein Engineering
Neil Berkley – CFO & Chief Business Officer
Conference Call Participants
Thomas Shrader – BTIG, LLC, Research Division
Pete Stavropoulos – Cantor Fitzgerald & Co., Research Division
Graig Suvannavejh – Mizuho Securities USA LLC, Research Division
Michael Riad – Morgan Stanley, Research Division
Steven Ionov – TD Cowen, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Alector Pipeline Webinar, Advancing Next Generation Medicines for Neurodegeneration. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Arnon Rosenthal, Chief Executive Officer. Please go ahead.
Arnon Rosenthal
Co-Founder, CEO & Director
Good morning and welcome, everyone. As you heard, I’m Arnon, Alector CEO and Co-Founder. We don’t see each other, but there are over 150 people registered to this seminar. So, I’m looking forward to a lively Q&A session after the presentation. So, for the people who know Alector for the last 10 years, you should know that we are now a very different company than we were in the past. Our mission remained the same, our resilience remained the same, but our strategy has fundamentally changed. In the last 10 years, we have developed immune checkpoint therapies for the brain immune cells as a therapeutic strategy for neurodegeneration. We now have an emerging portfolio of bispecific antibodies, enzymes, and nucleic acid therapies that are all driven by our blood-brain barrier technology and address more validated targets.
So, the probability of technical success of our second-generation targets is significantly higher than the completely novel targets we have
